Table 1. Patient characteristics.
|
Post treatmentb (n=41)
|
|||
|---|---|---|---|
| Group | Pretreatmenta (n=9) | RT (n=20) | RT+CT (n=21) |
| Age (range) | (43–75) | (52–80) | (38–69) |
| Type of surgery | |||
| Mastectomy | — | 3 | 2 |
| Breast conservation | — | 17 | 19 |
| Lymph nodes | |||
| Axillary clearance | 0 | 5 | 14 |
| Sentinel node | 8 | 11 | 7 |
| No axillary dissection | 1 | 4 | 0 |
| Cancer in situ | 1 | 2 | 0 |
| No. of involved nodes | |||
| ⩽3 | 0 | 0 | 11 |
| 4–8 | 1 | 1 | 4 |
| ⩾9 | 0 | 0 | 1 |
| negative | 8 | 15 | 5 |
| ER+ | 8 | 17 | 14 |
| PR+ | 8 | 10 | 9 |
| HER2+ | 1 | 4 | |
| HER2− | 1 | 6 | |
| Tumour size mm, median (range) | 14 (5–50) | 17 (7–30) | |
| <2 cm | 7 | 13 | 16 |
| ⩾2 cm | 2 | 7 | 5 |
| Adjuvant tamoxifen | 5 | 11 | 15 |
ER+=estrogen receptor positive; HER2+=human epidermal growth factor receptor 2; PR+=progestron receptor positive.
a
Blood samples were collected 1–3 days before primary surgery.
b
Blood samples collected after a median time 40 days.